Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1974 Sep;121(3):188–206.

Parkinson's disease and levodopa. A five-year follow-up and review.

C H Markham, L J Treciokas, S G Diamond
PMCID: PMC1129565  PMID: 4606887

Full text

PDF
188

Images in this article

192Figure 1.
on p.192
202Chart 9.
on p.202

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADAMS R., VAN BOGAERT L., VAN DER EECKEN H. [Nigro-striate and cerebello-nigro-striate degeneration. (Clinical uniqueness and pathological variability of presenile degeneration of the extrapyramidal rigidity type]. Psychiatr Neurol (Basel) 1961;142:219–259. [PubMed] [Google Scholar]
  2. ANDEN N. E., CARLSSON A., DAHLSTROEM A., FUXE K., HILLARP N. A., LARSSON K. DEMONSTRATION AND MAPPING OUT OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS. Life Sci. 1964 Jun;3:523–530. doi: 10.1016/0024-3205(64)90161-4. [DOI] [PubMed] [Google Scholar]
  3. Agid Y., Javoy F., Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat New Biol. 1973 Oct 3;245(144):150–151. doi: 10.1038/newbio245150a0. [DOI] [PubMed] [Google Scholar]
  4. Andrews J. M., Terry R. D., Spataro J. Striatonigral degeneration. Clinical-pathological correlations and response to stereotaxic surgery. Arch Neurol. 1970 Oct;23(4):319–329. doi: 10.1001/archneur.1970.00480280033004. [DOI] [PubMed] [Google Scholar]
  5. BERNHEIMER H., BIRKMAYER W., HORNYKIEWICZ O. [Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome]. Klin Wochenschr. 1961 Oct 15;39:1056–1059. doi: 10.1007/BF01487648. [DOI] [PubMed] [Google Scholar]
  6. BERTLER A., ROSENGREN E. Occurrence and distribution of dopamine in brain and other tissues. Experientia. 1959 Jan 15;15(1):10–11. doi: 10.1007/BF02157069. [DOI] [PubMed] [Google Scholar]
  7. BIRKMAYER W., HORNYKIEWICZ O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr. 1961 Nov 10;73:787–788. [PubMed] [Google Scholar]
  8. Beardsley J. V., Puletti F. Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment. Arch Neurol. 1971 Aug;25(2):145–150. doi: 10.1001/archneur.1971.00490020063007. [DOI] [PubMed] [Google Scholar]
  9. Bedard P., Larochelle L. Effect of section of the strionigral fibers on dopamine turnover in the forebrain of the rat. Exp Neurol. 1973 Nov;41(2):314–322. doi: 10.1016/0014-4886(73)90272-0. [DOI] [PubMed] [Google Scholar]
  10. Bird E. D., Mackay A. V., Rayner C. N., Iversen L. L. Reduced glutamic-acid-decarboxylase activity of post-mortem brain in Huntington's chorea. Lancet. 1973 May 19;1(7812):1090–1092. doi: 10.1016/s0140-6736(73)90398-x. [DOI] [PubMed] [Google Scholar]
  11. Björklund A., Nobin A., Stenevi U. Regeneration of central serotonin neurons after axonal degeneration induced by 5,6-dihydroxytryptamine. Brain Res. 1973 Feb 14;50(1):214–220. doi: 10.1016/0006-8993(73)90611-2. [DOI] [PubMed] [Google Scholar]
  12. CARLSSON A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959 Jun;11(2 Pt 2):490–493. [PubMed] [Google Scholar]
  13. Calne D. B., Reid J. L., Vakil S. D., Rao S., Petrie A., Pallis C. A., Gawler J., Thomas P. K., Hilson A. Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J. 1971 Sep 25;3(5777):729–732. doi: 10.1136/bmj.3.5777.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Calne D. B., Stern G. M., Spiers A. S., Laurence D. R. L-dopa in idiopathic parkinsonism. Lancet. 1969 Nov 8;2(7628):973–976. doi: 10.1016/s0140-6736(69)90536-4. [DOI] [PubMed] [Google Scholar]
  15. Campbell L. B., Jenden D. J. Gas chromatographic evaluation of the influence of oxotremorine upon the regional distribution of acetylcholine in rat brain. J Neurochem. 1970 Dec;17(12):1697–1699. doi: 10.1111/j.1471-4159.1970.tb11396.x. [DOI] [PubMed] [Google Scholar]
  16. Chase T. N. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism. Neurology. 1970 Dec;20(12 Suppl):36–40. [PubMed] [Google Scholar]
  17. Constantinidis J., Bartholini G., Geissbühler F., Tissot R. La barrière capillaire enzymatique pour la DOPA au niveau de quelques noyaux du tronc cérébral du rat. Experientia. 1970 Apr 15;26(4):381–383. doi: 10.1007/BF01896900. [DOI] [PubMed] [Google Scholar]
  18. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  19. Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
  20. Curtis D. R., Duggan A. W., Felix D. GABA and inhibition of Deiters' neurones. Brain Res. 1970 Sep 29;23(1):117–120. doi: 10.1016/0006-8993(70)90357-4. [DOI] [PubMed] [Google Scholar]
  21. Dehaene I., Bogaerts M. L-dopa in progressive supranuclear palsy. Lancet. 1970 Aug 29;2(7670):470–470. doi: 10.1016/s0140-6736(70)90089-9. [DOI] [PubMed] [Google Scholar]
  22. EHRINGER H., HORNYKIEWICZ O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–1239. doi: 10.1007/BF01485901. [DOI] [PubMed] [Google Scholar]
  23. Forno L. S., Alvord E. C., Jr The pathology of Parkinsonism. Part I. Some new observations and correlations. Contemp Neurol Ser. 1971;8:119–130. [PubMed] [Google Scholar]
  24. Goodwin F. K., Brodie H. K., Murphy D. L., Bunney W. E., Jr Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients. Lancet. 1970 May 2;1(7653):908–911. doi: 10.1016/s0140-6736(70)91044-5. [DOI] [PubMed] [Google Scholar]
  25. Greer M., Collins G. H., Anton A. H. Cerebral catecholamines after levodopa therapy. Arch Neurol. 1971 Nov;25(5):461–467. doi: 10.1001/archneur.1971.00490050095008. [DOI] [PubMed] [Google Scholar]
  26. HORNYKIEWICZ O. [The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease]. Wien Klin Wochenschr. 1963 May 3;75:309–312. [PubMed] [Google Scholar]
  27. Hattori T., Fibiger H. C., McGeer P. L., Maler L. Analysis of the fine structure of the dopaminergic nigrostriatal projection by electron microscopic autoradiography. Exp Neurol. 1973 Dec;41(3):599–611. doi: 10.1016/0014-4886(73)90053-8. [DOI] [PubMed] [Google Scholar]
  28. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  29. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966 Jun;18(2):925–964. [PubMed] [Google Scholar]
  30. Hunter K. R., Shaw K. M., Laurence D. R., Stern G. M. Sustained levodopa therapy in parkinsonism. Lancet. 1973 Oct 27;2(7835):929–931. doi: 10.1016/s0140-6736(73)92595-6. [DOI] [PubMed] [Google Scholar]
  31. Izumi K., Inoue N., Shirabe T., Miyazaki T., Kuroiwa Y. Failed levodopa therapy in striato-nigral degeneration. Lancet. 1971 Jun 26;1(7713):1355–1355. doi: 10.1016/s0140-6736(71)91914-3. [DOI] [PubMed] [Google Scholar]
  32. JOHANSEN K. REGIONAL DISTRIBUTION OF CIRCULATING BLOOD DURING SUBMERSION ASPHYXIA IN THE DUCK. Acta Physiol Scand. 1964 Sep-Oct;62:1–9. doi: 10.1111/j.1748-1716.1964.tb03945.x. [DOI] [PubMed] [Google Scholar]
  33. Katzman R., Björklund A., Owman C., Stenevi U., West K. A. Evidence for regenerative axon sprouting of central catecholamine neurons in the rat mesencephalon following electrolytic lesions. Brain Res. 1971 Feb 5;25(3):579–596. doi: 10.1016/0006-8993(71)90462-8. [DOI] [PubMed] [Google Scholar]
  34. Kemp J. M., Powell T. P. The connexions of the striatum and globus pallidus: synthesis and speculation. Philos Trans R Soc Lond B Biol Sci. 1971 Sep 30;262(845):441–457. doi: 10.1098/rstb.1971.0106. [DOI] [PubMed] [Google Scholar]
  35. Kemp J. M., Powell T. P. The site of termination of afferent fibres in the caudate nucleus. Philos Trans R Soc Lond B Biol Sci. 1971 Sep 30;262(845):413–427. doi: 10.1098/rstb.1971.0104. [DOI] [PubMed] [Google Scholar]
  36. Kemp J. M., Powell T. P. The structure of the caudate nucleus of the cat: light and electron microscopy. Philos Trans R Soc Lond B Biol Sci. 1971 Sep 30;262(845):383–401. doi: 10.1098/rstb.1971.0102. [DOI] [PubMed] [Google Scholar]
  37. Kemp J. M., Powell T. P. The synaptic organization of the caudate nucleus. Philos Trans R Soc Lond B Biol Sci. 1971 Sep 30;262(845):403–412. doi: 10.1098/rstb.1971.0103. [DOI] [PubMed] [Google Scholar]
  38. Kemp J. M., Powell T. P. The termination of fibres from the cerebral cortex and thalamus upon dendritic spines in the caudate nucleus: a study with the Golgi method. Philos Trans R Soc Lond B Biol Sci. 1971 Sep 30;262(845):429–439. doi: 10.1098/rstb.1971.0105. [DOI] [PubMed] [Google Scholar]
  39. Kim J. S., Bak I. J., Hassler R., Okada Y. Role of -aminobutyric acid (GABA) in the extrapyramidal motor system. 2. Some evidence for the existence of a type of GABA-rich strio-nigral neurons. Exp Brain Res. 1971;14(1):95–104. doi: 10.1007/BF00234913. [DOI] [PubMed] [Google Scholar]
  40. Klawans H. L., Jr, Paulson G. W., Ringel S. P., Barbeau A. Use of L-dopa in the detection of presymptomatic Huntington's chorea. N Engl J Med. 1972 Jun 22;286(25):1332–1334. doi: 10.1056/NEJM197206222862503. [DOI] [PubMed] [Google Scholar]
  41. Koella W. P., Sutin J. Extra-blood-brain-barrier brain structures. Int Rev Neurobiol. 1967;10:31–55. doi: 10.1016/s0074-7742(08)60150-6. [DOI] [PubMed] [Google Scholar]
  42. Korten J. J., Gabreels F. J., Joosten E. M. Undesirable prepubertal effects of levodopa. JAMA. 1973 Oct 15;226(3):355–355. [PubMed] [Google Scholar]
  43. LAVERTY R., MICHAELSON I. A., SHARMAN D. F., WHITTAKER V. P. THE SUBCELLULAR LOCALIZATION OF DOPAMINE AND ACETYLCHOLINE IN THE DOG CAUDATE NUCLEUS. Br J Pharmacol Chemother. 1963 Dec;21:482–490. doi: 10.1111/j.1476-5381.1963.tb02016.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Laitinen L. V. Slowly absorbed L-dopa preparation in the treatment of parkinsonism. Acta Neurol Scand. 1973;49(3):331–338. doi: 10.1111/j.1600-0404.1973.tb01306.x. [DOI] [PubMed] [Google Scholar]
  45. Langrall H. M., Joseph C. Status of the clinical evaluation of levodopa in the treatment of Parkinson's disease and syndrome. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):323–331. doi: 10.1002/cpt1971122part2323. [DOI] [PubMed] [Google Scholar]
  46. Lloyd K. G., Hornykiewicz O. L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy. Nature. 1973 Jun 29;243(5409):521–523. doi: 10.1038/243521a0. [DOI] [PubMed] [Google Scholar]
  47. Loranger A. W., Goodell H., McDowell F. H., Lee J. E., Sweet R. D. Intellectual impairment in Parkinson's syndrome. Brain. 1972;95(2):405–412. doi: 10.1093/brain/95.2.405. [DOI] [PubMed] [Google Scholar]
  48. Lundberg P. O. Blood levels of FSH, LH, TSH, and GH in parkinsonian patients before and during L-dopa treatment. Acta Neurol Scand. 1972;48(4):427–432. doi: 10.1111/j.1600-0404.1972.tb07564.x. [DOI] [PubMed] [Google Scholar]
  49. Markham C. H. The choreoathetoid movement disorder induced by levodopa. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):340–343. doi: 10.1002/cpt1971122part2340. [DOI] [PubMed] [Google Scholar]
  50. Markham C., Diamond S. G., Treciokas L. J. Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch Neurol. 1974 Aug;31(2):128–133. doi: 10.1001/archneur.1974.00490380076010. [DOI] [PubMed] [Google Scholar]
  51. Marsh G. G., Markham C. H. Does levodopa alter depression and psychopathology in Parkinsonism patients? J Neurol Neurosurg Psychiatry. 1973 Dec;36(6):925–935. doi: 10.1136/jnnp.36.6.925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Marsh G. G., Markham C. M., Ansel R. Levodopa's awakening effect on patients with Parkinsonism. J Neurol Neurosurg Psychiatry. 1971 Jun;34(3):209–218. doi: 10.1136/jnnp.34.3.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. McDowell F., Lee J. E., Swift T., Sweet R. D., Ogsbury J. S., Kessler J. T. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa). Ann Intern Med. 1970 Jan;72(1):29–35. doi: 10.7326/0003-4819-72-1-29. [DOI] [PubMed] [Google Scholar]
  54. McGeer P. L., McGeer E. G., Fibiger H. C., Wickson V. Neostriatal choline acetylase and cholinesterase following selective brain lesions. Brain Res. 1971 Dec 10;35(1):308–314. doi: 10.1016/0006-8993(71)90625-1. [DOI] [PubMed] [Google Scholar]
  55. Mena I., Court J., Fuenzalida S., Papavasiliou P. S., Cotzias G. C. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. N Engl J Med. 1970 Jan 1;282(1):5–10. doi: 10.1056/NEJM197001012820102. [DOI] [PubMed] [Google Scholar]
  56. Mena I., Marin O., Fuenzalida S., Cotzias G. C. Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology. 1967 Feb;17(2):128–136. doi: 10.1212/wnl.17.2.128. [DOI] [PubMed] [Google Scholar]
  57. Mindham R. H. Psychiatric symptoms in Parkinsonism. J Neurol Neurosurg Psychiatry. 1970 Apr;33(2):188–191. doi: 10.1136/jnnp.33.2.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Mones R. J. An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy. J Neurol Neurosurg Psychiatry. 1973 Jun;36(3):362–367. doi: 10.1136/jnnp.36.3.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Moore R. Y., Björklund A., Stenevi U. Plastic changes in the adrenergic innervation of the rat septal area in response to denervation. Brain Res. 1971 Oct 8;33(1):13–35. doi: 10.1016/0006-8993(71)90303-9. [DOI] [PubMed] [Google Scholar]
  60. Obata K., Takeda K., Shinozaki H. Further study on pharmacological properties of the cerebellar-induced inhibition of deiters neurones. Exp Brain Res. 1970 Nov 26;11(4):327–342. doi: 10.1007/BF00237907. [DOI] [PubMed] [Google Scholar]
  61. PENTSCHEW A., EBNER F. F., KOVATCH R. M. EXPERIMENTAL MANGANESE ENCEPHALOPATHY IN MONKEYS. A PRELIMINARY REPORT. J Neuropathol Exp Neurol. 1963 Jul;22:488–499. doi: 10.1097/00005072-196307000-00010. [DOI] [PubMed] [Google Scholar]
  62. Perry T. L., Hansen S., Kloster M. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J Med. 1973 Feb 15;288(7):337–342. doi: 10.1056/NEJM197302152880703. [DOI] [PubMed] [Google Scholar]
  63. Precht W., Yoshida M. Blockage of caudate-evoked inhibition of neurons in the substantia nigra by picrotoxin. Brain Res. 1971 Sep 10;32(1):229–233. doi: 10.1016/0006-8993(71)90171-5. [DOI] [PubMed] [Google Scholar]
  64. Raisman G., Field P. M. A quantitative investigation of the development of collateral reinnervation after partial deafferentation of the septal nuclei. Brain Res. 1973 Feb 28;50(2):241–264. doi: 10.1016/0006-8993(73)90729-4. [DOI] [PubMed] [Google Scholar]
  65. Raisman G. Neuronal plasticity in the septal nuclei of the adult rat. Brain Res. 1969 Jun;14(1):25–48. doi: 10.1016/0006-8993(69)90029-8. [DOI] [PubMed] [Google Scholar]
  66. Rivera-Calimlim L., Dujovne C. A., Morgan J. P., Lasagna L., Bianchine J. R. L-dopa treatment failure: explanation and correction. Br Med J. 1970 Oct 10;4(5727):93–94. doi: 10.1136/bmj.4.5727.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. STEELE J. C., RICHARDSON J. C., OLSZEWSKI J. PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol. 1964 Apr;10:333–359. doi: 10.1001/archneur.1964.00460160003001. [DOI] [PubMed] [Google Scholar]
  68. Sethy V. H., Van Woert M. H. Effect of L-DOPA on brain acetylcholine and choline in rats. Neuropharmacology. 1973 Jan;12(1):27–31. doi: 10.1016/0028-3908(73)90128-7. [DOI] [PubMed] [Google Scholar]
  69. Sharpe J. A., Rewcastle N. B., Lloyd K. G., Hornykiewicz O., Hill M., Tasker R. R. Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. J Neurol Sci. 1973 Jul;19(3):275–286. doi: 10.1016/0022-510x(73)90091-9. [DOI] [PubMed] [Google Scholar]
  70. Sirtori C. R., Bolme P., Azarnoff D. L. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med. 1972 Oct 12;287(15):729–733. doi: 10.1056/NEJM197210122871501. [DOI] [PubMed] [Google Scholar]
  71. Stern P. H., McDowell F., Miller J. M., Robinson M. B. Levodopa therapy effects on natural history of Parkinsonism. Arch Neurol. 1972 Dec;27(6):481–485. doi: 10.1001/archneur.1972.00490180017005. [DOI] [PubMed] [Google Scholar]
  72. Treciokas L. J., Ansel R. D., Markham C. H. One to two year treatment of Parkinson's disease with levodopa. Calif Med. 1971 May;114(5):7–14. [PMC free article] [PubMed] [Google Scholar]
  73. VONEIDA T. J. An experimental study of the course and destination of fibers arising in the head of the caudate nucleus in the cat and monkey. J Comp Neurol. 1960 Aug;115:75–87. doi: 10.1002/cne.901150107. [DOI] [PubMed] [Google Scholar]
  74. Yahr M. D., Duvoisin R. C., Hoehn M. M., Schear M. J., Barrett R. E. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. Trans Am Neurol Assoc. 1968;93:56–63. [PubMed] [Google Scholar]
  75. Yoshida M., Precht W. Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers. Brain Res. 1971 Sep 10;32(1):225–228. doi: 10.1016/0006-8993(71)90170-3. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES